文献速递精神分裂症与精神病性障碍焦虑、强迫与应激相关障碍

聚焦创伤的CBTp整合治疗共病PTSD与精神病:STAR多中心随机试验

Trauma-focused therapy integrated with cognitive behavioural therapy for psychosis for people with post-traumatic stress disorder and psychosis (the STAR trial): a multicentre, pragmatic, randomised trial in the UK.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

STAR试验在英国五中心随机分配305名共病PTSD与精神病的成人,比较聚焦创伤的CBTp联合常规治疗与单用常规治疗。

要点

  • PTSD缓解率治疗组50%、常规组22%,需治疗人数为4。
  • 27项次要结局中22项显著改善,但幻听、社交功能等无显著效果。

核心结论

  • 聚焦创伤的CBTp对共病精神病与PTSD患者安全、可接受性高且有效,不应再被剥夺心理干预机会。

研究设计与样本

  • STAR为评估者盲、平行组、实用性随机对照试验,在英国五个中心开展。
  • 共随机分配305名共病PTSD与精神病的成人(常规治疗151人,聚焦创伤CBTp联合常规治疗154人),按站点分层、随机区组1:1分配。
  • 聚焦创伤CBTp为灵活、个体化、基于公式化的治疗,整合创伤聚焦成分与CBTp,持续9个月。
  • 主要结局为4个月(治疗中期)和9个月(主要终点)的CAPS-5评估的PTSD症状严重度。

关键数值与推荐

  • PTSD缓解需治疗人数为4。

临床怎么用

  • 对共病PTSD与精神病的成人,可提供聚焦创伤的CBTp联合常规治疗,疗程9个月。
  • 治疗可改善PTSD症状、妄想、偏执、其他模态幻觉、自杀意念、抑郁、焦虑及心理康复。
  • 对幻听、参照信念、物质使用及社交功能无显著改善,需另行针对性干预。

局限性

  • 27项次要结局未校正多重比较,部分阳性结果需谨慎解读。
  • 9个月时仅79%参与者提供主要结局数据,次要结局数据完整率为55-81%。
  • 样本以白人(76%)为主,结果外推至其他族裔需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with psychosis have high rates of post-traumatic stress disorder (PTSD), which is associated with a poor prognosis. We aimed to investigate the effectiveness of a trauma-focused therapy integrated with cognitive behavioural therapy for psychosis (CBTp) in people with psychosis. METHODS: STAR was a rater-blind, parallel-group, pragmatic randomised controlled trial conducted across five UK sites. We randomly assigned (1:1) adults with co-occurring PTSD and psychosis in secondary care to trauma-focused CBTp plus treatment as usual or treatment as usual only, using randomly varying block size, stratified by site. Trauma-focused CBTp is a flexible, individualised, formulation-based therapy integrating trauma-focused therapeutic components with CBTp, lasting 9 months. The primary outcome was PTSD symptom severity, assessed using clinician-administered PTSD scale for DSM-5 (CAPS-5), at 4 months (mid-therapy) and 9 months (primary endpoint). Secondary outcomes were (1) percentage of participants showing PTSD remission from diagnosis and clinically significant change, individual symptom clusters, post-traumatic cognitions, and dissociation; (2) psychosis symptoms; (3) mood disorders; (4) psychological recovery; and (5) social functioning, assessed at the same timepoints. We used linear mixed models in the intention-to-treat population at 9 months, incorporating all outcome data including at 4 months. Lived experience experts were integral throughout the research. This study was registered prospectively with ISRCTN, ISRCTN93382525. FINDINGS: Between Oct 1, 2020, and March 20, 2023, we randomly assigned 305 participants (151 [49·5%] to treatment as usual and 154 [50·5%] to trauma-focused CBTp plus treatment as usual). The mean age of participants was 38·9 years (SD 12·4). 127 (42%) participants were men, 171 (56%) were women and seven (2%) were non-binary or preferred not to say; 232 (76%) were White. All reported repeated and multiple traumas. Of 154 in the trauma-focused CBTp plus treatment-as-usual group, 144 (94%) engaged with therapy and 146 (95%) received a minimal therapeutic dose. 267 (88%) of 305 participants attended a follow-up assessment (4 months, 9 months, or both); at 9 months, 241 (79%) participants provided primary outcome data and 169-248 (55-81%) provided secondary outcome data. There were significant effects on CAPS-5 scores (adjusted mean difference in PTSD symptom severity -8·67 [95% CI -13·41 to -3·94]; p=0·0003; Cohen's d -0·73) and on 22 (81%) of 27 secondary outcomes, unadjusted for multiple testing (Cohen's d ranging from -0·26 to -0·82), including all PTSD outcomes (except derealisation and depersonalisation); delusions, paranoia, and hallucinations in other modalities; suicidal ideation, depression, anxiety, and stress; and psychological recovery. There were no effects on voices, referential beliefs, substance use, or social functioning (Cohen's d ranging from -0·05 to -0·28). 62 (50%) of 125 participants in the therapy group showed PTSD remission compared with 25 (22%) of 116 in the treatment-as-usual group (odds ratio [OR; PTSD present] 0·11, 95% CI 0·03-0·32; p=0·0001) and 56 (45%) participants in the therapy group compared with 31 (27%) in the treatment-as-usual group had clinically significant change in CAPS-5 score (OR 4·45, 95% CI 1·59-12·44; p=0·0044; number needed to treat for PTSD remission was 4). No serious adverse event was unexpected and related to trial procedures (78 reported in each group), with the most common being physical illness or injury. INTERPRETATION: Trauma-focused CBTp is safe, highly acceptable, and effective in people with co-occurring psychosis and PTSD. This underserved population should no longer be denied access to psychological interventions to treat their trauma sequelae. FUNDING: UK National Institute for Health and Care Research (Health Technology Assessment).

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Peters E, Swan S, Underwood R, et al. Trauma-focused therapy integrated with cognitive behavioural therapy for psychosis for people with post-traumatic stress disorder and psychosis (the STAR trial): a multicentre, pragmatic, randomised trial in the UK. Lancet Psychiatry. 2026. PMID: 42309103. doi:10.1016/S2215-0366(26)00090-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。